SecBot SecBot

ANIX

Anixa Biosciences Inc
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000715446 Biotech & Drug Discovery
$2.99 +0.21 (+7.55%)
Oct 23 4:00 PM ET · prev $2.78
Market cap
$96.6M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
🔒 Subscribers only
1 year
−27.8%
from $4.14 · Oct 24
30 days
+7.6%
from $2.78
52-week range
$2.35–5.22
−43% from high · low Jun 10
Avg volume 20D
238.9K
shares / day
Short interest
1.35M
≈3.9% of shares · +28.0%
Days to cover
3.7
at average volume
Insider net
+$451.7K
4 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 1/2
Strongest BULLISH Four Anixa insiders, including the CEO, President/CFO, and two directors, made open-market purchases…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • B Jun 12 to Jun 16 2 days of insider buys: $60.0K by 2 insiders, avg $2.52
  • B Jul 10 to Jul 31 6 days of insider buys: $139.8K by 2 insiders, avg $3.41
  • X Jul 31 Short interest jumps 26.5% to 1.09M
  • B Sep 10 2 insiders buy $49.4K at $2.74
  • B Sep 23 to Sep 30 3 days of insider buys: $180.8K by 4 insiders, avg $2.72
  • X Sep 30 Short interest jumps 28.0% to 1.35M
  • B Oct 22 1 insider buy $21.8K at $2.72

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $451.7K at an average $2.87. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +28.0% to 1.35M shares. 3.7 days to cover, ≈3.9% of shares.

  • TrendDOWNTREND

    0% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
MARSHALL WACE, LLPADD328,332$919.3K
LPL Financial LLCADD111,535$312.3K
Kestra Advisory Services, LLCTRIM38,000$106.4K
Corient Private Wealth LPADD37,400$104.7K
MORGAN STANLEYTRIM6,143$17.2K
ROYAL BANK OF CANADAADD1,497$4.0K
SCHRODER INVESTMENT MANAGEMENT GROUPEXIT0$0.00
SCHRODER INVESTMENT MANAGEMENT GROUPNEW195,025$26.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy2Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 22, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$451.7K
bought · 4 insiders
$0
sold · 0 insiders
+4.2%
vs their $2.87 cost
DateInsiderTypeValue
Oct 22, 2026
KUMAR AMIT
Chief Executive Officer
BUY$21.8K
Sep 30, 2026
Catelani Michael
President, COO, & CFO
BUY$15.6K
Sep 24, 2026
KUMAR AMIT
Chief Executive Officer
BUY$19.5K
Sep 24, 2026
Baskies Arnold M
Director
BUY$13.8K
Sep 23, 2026
Titterton Lewis H jr
Director
BUY$131.9K
Sep 10, 2026
Titterton Lewis H jr
Director
BUY$27.3K
Sep 10, 2026
KUMAR AMIT
Chief Executive Officer
BUY$13.8K
Sep 10, 2026
KUMAR AMIT
Chief Executive Officer
BUY$8.3K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,350,212
shares short
+28.0%
vs prior settlement
3.7
days to cover
≈3.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Insider
KUMAR AMIT bought 8,000 shares
Chief Executive Officer @ $2.72 ($21.8K)
Oct 13, 2026 Other
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference
Sep 30, 2026 SEC
Four Anixa insiders, including the CEO, President/CFO, and two directors, made open-market purchases totaling $181K…
CLUSTER — Impact 5/10
Sep 30, 2026 Insider
Catelani Michael bought 5,500 shares
President, COO, & CFO @ $2.84 ($15.6K)
Sep 28, 2026 SEC
Two Anixa insiders, including the CEO and a director, made open-market purchases totaling $151K in late September…
CLUSTER — Impact 4/10
Sep 24, 2026 Insider
KUMAR AMIT bought 7,000 shares
Chief Executive Officer @ $2.78 ($19.5K)
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — ADD
328,332 shares ($919.3K)
Jun 30, 2026 Inst.
LPL Financial LLC — ADD
111,535 shares ($312.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 13, 2026
Press release
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/…
Sep 30, 2026
Short interest
Short Interest: ANIX up 28% to 1.4M shares
Settlement 2026-09-30 | Days to cover: 3.69 | ≈3.88% of shares outstanding (est.)
Sep 9, 2026
Press release
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused…
Sep 8, 2026
Earnings date
ANIX Q3 2026 Earnings Scheduled — 2026-09-08
Sep 3, 2026
Press release
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt…

SecBot reports

3 filings · 3 bullish · 0 bearish
All ANIX filing & press-release reports (3)